Skip to main content
Equibles
CVKD logo

CVKD · Cadrenal Therapeutics, Inc. · Metrics

Track CVKD — free

Use CVKD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CVKD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.94 0.00 (-0.47%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the date the accompanying financial statements are issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$3.38M
Shares
3.57M
Volume · Oct 29 44.03K Avg daily vol (3M) 461.96K

CVKD metrics

66 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.94
Market cap
$3.38M

Price action

20 metrics
Price change (1W)
-7.1%
Price change (30D)
-13.0%
Price change (3M)
-51.9%
Price change (6M)
-83.0%
Price change (YTD)
-86.0%
Price change (1Y)
-92.6%
Trailing year
Price change (5Y)
—
52-week high
$13.67
52-week low
$0.87
Change from 52-week high
-93.1%
Change from 52-week low
+8.7%
Annualized volatility
101.4%
Annualized volatility (3M)
87.2%
Beta
1.9
RSI (14D)
41.0
Price vs SMA 50
-18.8%
Price vs SMA 200
-76.4%
Avg volume (3M)
461,494
Relative volume
0.1
Average dollar volume
$733,505

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.57M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.8
reciprocal yield 121.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-341.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-08-11

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$11.65M
Net income (TTM)
−$11.54M
Trailing 12 months
Diluted EPS (TTM)
$-4.86
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-4.97
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-4.92
Operating cash flow per diluted share (TTM)
$-4.38
Free cash flow per diluted share (TTM)
$-6.43
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$1.21
Stock compensation per diluted share (TTM)
$0.72
Book value per share
$1.17

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+48.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-282.1%
Return on assets
-206.5%
Debt / equity
0.0
Current ratio
3.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$2.39M
Latest balance sheet
Cash & equivalents
$2.39M
Total assets
$5.59M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$10.16M
Capital expenditures (TTM)
$5,104
R&D (TTM)
$2.83M
SG&A (TTM)
—
Stock compensation (TTM)
$1.72M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
19
13F filer change QoQ
-1
Institutional ownership
3.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
1.1%
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+243.5%
Holder tenure
2.7
Price vs estimated holder cost
-55.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.9%

Short interest

3 metrics
Short interest
7.9%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1937993 CUSIP 127636207 13F (30d) 5 filings 5 filers Visit website